プロホルモンの分裂予測は,非インクレチン抗肥満ペプチドを発見
Laetitia Coassolo1,2,3, Niels B Danneskiold-Samsøe1,2, Quennie Nguyen1
1Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Nature
|March 5, 2025
まとめ
研究者は動物モデルで 食物の摂取を減らし 肥満と闘う新しいペプチド BRP を発見しました このペプチドは 計算による薬物発見により 副作用のない 体重管理の新たな治療法となる可能性があります
科学分野:
- 生物化学
- 内分泌学
- 薬理学について
背景:
- ペプチドホルモンは エネルギーバランスを調整します
- プロホルモンコンバーターゼ1/3 (PCSK1) は,グルカゴン型ペプチド1 (GLP-1) のような治療標的を含むペプチド処理に不可欠です.
- PCSK1生成ペプチドの全範囲とその機能は完全に理解されていません.
研究 の 目的:
- プロホルモンコンバータゼによって生成された,以前に特徴づけられていないヒトタンパク質分解ペプチドの断片を体系的にマッピングする.
- 新しい生物活性ペプチドを特定し, 治療的な応用が可能です.
- 新たに発見されたペプチドBRPの 抗肥満効果とメカニズムを調査する.
主な方法:
- 2,600以上のヒトタンパク質分解ペプチドの断片をマッピングするために,コンピュータによる薬物発見が採用されました.
- 新しい12メルペプチド,BRINP2関連ペプチド (BRP) が特定されました.
- マウスとブタへのBRPの薬理学的投与は,食物摂取と体重への影響を評価するために使用されました.
主要な成果:
- 2600以上のペプチドの断片を特定した.
- 12マーペプチド (BRP) の発見と特徴付け
- BRPの投与は,吐き気や嫌悪感を伴わず,マウスと豚の食物の摂取を減少させ,肥満抑制効果を示した.
- BRPは中央のFOS活性化を誘発し,レプチン,GLP-1受容体,およびメラノコルチン4受容体とは独立に作用した.
結論:
- 新しい生物活性ペプチドの識別を可能にする新しい計算方法があります.
- BRPは薬理学的に検証されたペプチドで,体重を調節する治療的可能性があります.
- BRPは抗肥満治療の 新しく有望な道を示しています
さらに関連する動画
09:22Multi-Faceted Mass Spectrometric Investigation of Neuropeptides in Callinectes sapidus
Published on: May 31, 2022
2.4K
09:16Mixed Primary Cultures of Murine Small Intestine Intended for the Study of Gut Hormone Secretion and Live Cell Imaging of Enteroendocrine Cells
Published on: April 20, 2017
15.4K
関連する概念動画
Glucagon-like Receptor Agonists
290
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
290
Hormonal Regulation
43.1K
Hormones regulate a significant portion of digestion through activation of the neuroendocrine system. The neuroendocrine system of digestion contains many different hormones all with multiple functions that are both, directly and indirectly, involved in digestion.
43.1K
Regulation of Food Intake
174
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
174
Protein Digestion
102.0K
Protein digestion begins in the stomach, where the highly acidic environment can easily disrupt protein structure by exposing the peptide bonds of polypeptide chains. After polypeptide chains are broken into individual amino acids by a series of digestive enzymes, the amino acids are transported to the liver via the bloodstream to produce energy.
102.0K
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
Dipeptidyl Peptidase 4 Inhibitors
161
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
161
